Loading...
The 2024 American Society of Clinical Oncology (ASCO) annual meeting, held May 30 to June 3 in Chicago, highlighted important advances in treatment of hematologic cancers. Here, Associate Editor Dr. Michael Williams reviews several key trials.
The benefit of rituximab maintenance (RM) therapy following induction immunochemotherapy in mantle cell lymphoma (MCL) has not been fully defined. This multicenter, retrospective study assessed outcomes among patients treated from 2007 to 2020 with front-line bendamustine plus rituximab (BR) without autologous stem cell transplantation consolidation. Patients in complete or partial remission at 3 months post–BR completion were included (abs…